NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
24 févr. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a...
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
27 janv. 2022 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The...
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
20 janv. 2022 12h10 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of...
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
18 janv. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug...
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
10 janv. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships. Ms. Damkier will be...
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
05 janv. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the...
NeuroMetrix Reports Q3 2021 Financial Results
21 oct. 2021 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader...
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
20 oct. 2021 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based...
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
14 oct. 2021 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on...
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device
06 oct. 2021 18h42 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as...